NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets reduced their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 1.1 %

NYSE:NBY opened at $0.69 on Tuesday. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $9.08. The firm’s fifty day simple moving average is $0.62 and its 200 day simple moving average is $0.70. The firm has a market capitalization of $3.40 million, a PE ratio of -0.01 and a beta of 0.65.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). NovaBay Pharmaceuticals had a negative net margin of 102.72% and a negative return on equity of 7,293.78%. The company had revenue of $2.44 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, analysts anticipate that NovaBay Pharmaceuticals will post -3.26 EPS for the current fiscal year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.